Loading market dashboard
Labcorp Holdings Inc.
LHHealthcareNYSEUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Labcorp Holdings Inc. (LH) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Labcorp joins a national CRC trial as exclusive genetic testing provider, expanding Invitae-based testing and supporting cancer research.
Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer PR Newswire BURLINGTON,
Collaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family members Research will also assess the clinical impact of broader genetic testing in colorectal cancer care BURLINGTON, N.C., May 29, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced a collaboration with the Alliance for Clinical Trials in Oncology to advance a national, multicenter clinical trial for patients newly diagnosed with colorectal cancer (CRC).
New pharmacogenomic test detects all DPYD variants recommended by the Association for Molecular Pathology to support safer, more personalized cancer treatment BURLINGTON, N.C., May 28, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the availability of its expanded DPYD Genotyping test to help identify cancer patients who may be at increased risk for severe or life-threatening side effects from fluoropyrimidine chemotherapy.
Investors looking for stocks in the Medical Services sector might want to consider either Labcorp Holdings (LH) or Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now?
BURLINGTON, N.C., May 27, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that the company will present at the 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3, from 12:15 pm to 12:45 pm ET.
Labcorp (LH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
LH gains from specialty testing growth, acquisitions and AI initiatives, but currency swings and macro pressures remain risks.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
MyLabcorp connects lab results, educational content and AI-enabled features in a secure, personalized mobile experience Leverages OpenAI models designed to help users understand their results, ask questions and identify patterns over time BURLINGTON, N.C., May 20, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the launch of MyLabcorp ™ , an AI-powered mobile app that brings together lab results, AI-enabled features and clinical guideline-based content in a secure, personalized mobile experience.
Labcorp's full test menu will be available through Epic's Aura platform Integration builds on the successful deployment of Invitae genetic testing and accelerates access to the latest genetic and specialty diagnostics through Aura Collaboration will help reduce IT complexity, streamline lab ordering and improve access to diagnostic innovation for hospitals and health systems using Epic nationwide BURLINGTON, N.C., May 12, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration with Epic, the nation's leading electronic health record (EHR) supporting hospitals and health systems.
Investors interested in stocks from the Medical Services sector have probably already heard of Labcorp Holdings (LH) and Charles River Laboratories (CRL). But which of these two stocks offers value investors a better bang for their buck right now?
Labcorp (LH) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Labcorp's shares rise after Q1 beats on earnings and revenues, with growth across segments and a higher 2026 outlook signaling continued momentum.
Labcorp Holdings Inc. (LH) Q1 2026 Earnings Call Transcript
Labcorp Holdings (NYSE:LH) shares are up, up 1.46%, on Thursday as the company reported strong first-quarter results and raised its full-year guidance.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The headline numbers for Labcorp (LH) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Labcorp Holdings (LH) came out with quarterly earnings of $4.25 per share, beating the Zacks Consensus Estimate of $4.09 per share. This compares to earnings of $3.84 per share a year ago.
Labcorp raised its full-year profit and revenue forecast on Thursday after posting quarterly results above expectations as demand for diagnostic testing remained steady.
Q1 2026 revenue was $3.54 billion. The revenue estimate was $3,504.54 million.Diluted EPS was $3.35. The EPS estimate was $3.09.Adjusted EPS was $4.25, up 10.6
Results from Operations for first quarter 2026 versus first quarter 2025: Revenue: $3.54 billion vs. $3.35 billion, up 5.8% Diluted EPS: $3.35 vs.
Beyond analysts' top-and-bottom-line estimates for Labcorp (LH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2026.
Solventum (SOLV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Labcorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BURLINGTON, N.C., April 22, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide availability of Agilent Technologies' PD-L1 IHC 22C3 pharmDx, the only companion diagnostic approved by the U.S. Food and Drug Administration (FDA) to identify patients with platinum-resistant ovarian cancer who may be eligible for Merck's KEYTRUDA®.i KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) are the first FDA-approved PD-1 inhibitors available as part of a complete treatment regimen for eligible patients with platinum-resistant ovarian cancer.ii Helping Patients Access Critical New Treatment Options Approximately 80% of individuals with ovarian cancer experience recurrence after initial therapy, and many develop resistance to platinum-based chemotherapy, leading to limited treatment options and poor survival outcomes.
Labcorp (LH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Investors interested in Medical Services stocks are likely familiar with Labcorp Holdings (LH) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
LH heads into Q1 earnings results with rising diagnostics demand, new partnerships, and AI-driven tools boosting growth across testing and consumer health.
BOSTON--(BUSINESS WIRE)--d-wise (an Instem company), a leader in statistical computing infrastructure and clinical trial transparency, today announced the appointment of Christine Oliver as its President. Christine brings over two decades of executive leadership in clinical technology, most recently serving as CEO of Beaconcure, an AI company focused on automating the clinical data validation process in biometrics. Prior to that, she served as CEO of endpoint Clinical, a market leader in random.
Birch Hill Investment Advisors LLC lessened its position in Labcorp Holdings Inc. (NYSE: LH) by 31.0% during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 82,505 shares of the medical research company's stock after selling 37,071 shares during the period.
Assetmark Inc. raised its stake in shares of Labcorp Holdings Inc. (NYSE: LH) by 3.4% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 71,373 shares of the medical research company's stock after acquiring an additional 2,341 shares during the
First FDA-cleared rapid fentanyl test of its kind made in the United States designed to help emergency department and hospital teams act quickly when every second counts Fentanyl Urine Visual Test is available through Labcorp Point of Care, previously known as MEDTOX Diagnostics BURLINGTON, N.C., April 15, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the launch of the Labcorp Fentanyl Urine Visual Test, the first U.S. Food and Drug Administration (FDA)-cleared rapid fentanyl test of its kind manufactured in the United States.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Platform leverages agentic AI and diverse healthcare datasets to transform and speed drug development BURLINGTON, N.C., April 14, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced a new AI-powered real-world data platform, designed to help researchers and biopharmaceutical companies analyze Alzheimer's disease-related data faster.
Collaboration aims to speed the discovery, development and national availability of specialized pediatric diagnostics BURLINGTON, N.C. and PHILADELPHIA, April 13, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and Children's Hospital of Philadelphia (CHOP), the nation's first pediatric hospital, announced today a strategic collaboration to accelerate the discovery, development and nationwide availability of specialized pediatric diagnostics.
Massachusetts Financial Services Co. MA lessened its position in shares of Labcorp Holdings Inc. (NYSE: LH) by 4.2% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 570,075 shares of the medical research company's stock after selling 25,036 shares during the period.
BURLINGTON, N.C., April 9, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock.
Labcorp's expansion in specialty testing and efficiency gains support growth, but macroeconomic and competitive pressures could weigh on its outlook.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BURLINGTON, N.C., March 31, 2026 /PRNewswire/ -- Labcorp Holdings Inc.
Allspring Global Investments Holdings LLC increased its holdings in Labcorp Holdings Inc. (NYSE: LH) by 10.4% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,204,276 shares of the medical research company's stock after purchasing an additional 207,962 shares during the period.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Nordea Investment Management AB decreased its holdings in shares of Labcorp Holdings Inc. (NYSE: LH) by 36.4% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 967,679 shares of the medical research company's stock after selling 553,253 shares during
Labcorp (LH) reported earnings 30 days ago. What's next for the stock?
SAN DIEGO, March 18, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration to advance precision oncology through innovative applications of next-generation sequencing (NGS) solutions across the healthcare ecosystem. Projects are expected to include promoting equitable access to cancer biomarker testing by bringing it closer to patients through new distributed test offerings; generating evidence to facilitate payer coverage; and developing new tests to address areas of unmet need.
Banco Bilbao Vizcaya Argentaria S.A. lessened its stake in Labcorp Holdings Inc. (NYSE: LH) by 55.3% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,329 shares of the medical research company's stock after selling 18,987 shares during the period. Banco Bilbao
Cinctive Capital Management LP bought a new stake in shares of Labcorp Holdings Inc. (NYSE: LH) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 11,486 shares of the medical research company's stock, valued at approximately $3,297,000. Other hedge funds have also made
Labcorp Holdings Inc. (NYSE: LH - Get Free Report) has received a consensus rating of "Moderate Buy" from the twelve ratings firms that are currently covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 1-year price objective
8 Knots Management LLC raised its stake in Labcorp Holdings Inc. (NYSE: LH) by 96.6% during the undefined quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 204,859 shares of the medical research company's stock after buying an additional 100,675 shares during the quarter. Labcorp
Glenmede Investment Management LP cut its holdings in Labcorp Holdings Inc. (NYSE: LH) by 1.6% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 270,547 shares of the medical research company's stock after selling 4,365 shares during the quarter. Glenmede Investment Management
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
